WILLIAMS AND JENSEN, PLLC for ELI LILLY & COMPANY
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep.Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| CHRISTOPHER E. WILCOX | Regional Staff Asst & Staff Asst, Sen. Moynihan ;LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. FY 2021 Appropriations. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| MELINDA M MAXFIELD | — |
| GEORGE OLSEN | — |
| CHRISTOPHER E. WILCOX | Regional Staff Asst & Staff Asst, Senator Moynihan; LA, Leg Counsel, LD & Counsel, Rep Arcuri; LD & Counsel, Rep Demings |
Taxation/Internal Revenue Code TAX
International and domestic tax issues. Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | — |
Medicare/Medicaid MMM
Policies impacting Medicare Part D and Part B reimbursement policies. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Budget/Appropriations BUD
Policies impacting Medicare Part D. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Financial Services and General Government Federal Trade Commission report. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | Sch C, Treasury; LD Rep Scott McInnis |
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shrd Employee, Ofc of the Speaker and Ofc of VA 7; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep Christopher Cox |
| CHRISTOPHER E. WILCOX | Regional Staff Asst & Staff Asst, Sen. Moynihan ;LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
Trade (domestic/foreign) TRD
Issues related to pharmaceutical manufacturing and development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep.Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs |
| CHRISTOPHER E. WILCOX | Regional Staff Asst & Staff Asst, Sen. Moynihan ;LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.